Research autopsy programmes in oncology: shared experience from 14 centres across the world

Author:

Geukens Tatjana1,Maetens Marion1,Hooper Jody E2,Oesterreich Steffi3,Lee Adrian V3,Miller Lori3,Atkinson Jenny M3,Rosenzweig Margaret3,Puhalla Shannon3,Thorne Heather45,Devereux Lisa45,Bowtell David4,Loi Sherene45,Bacon Eliza R6,Ihle Kena6,Song Mihae6,Rodriguez‐Rodriguez Lorna6,Welm Alana L7,Gauchay Lisa7,Murali Rajmohan8,Chanda Pharto8,Karacay Ali8,Naceur‐Lombardelli Cristina9,Bridger Hayley10,Swanton Charles111213,Jamal‐Hanjani Mariam121314,Kollath Lori15,True Lawrence15,Morrissey Colm15,Chambers Meagan15,Chinnaiyan Arul M16,Wilson Allecia16,Mehra Rohit16ORCID,Reichert Zachery16,Carey Lisa A17,Perou Charles M17,Kelly Erin17,Maeda Daichi18,Goto Akiteru19,Kulka Janina20,Székely Borbála2021,Szasz A Marcell22,Tőkés Anna‐Mária20,Van Den Bogaert Wouter23ORCID,Floris Giuseppe24ORCID,Desmedt Christine1ORCID

Affiliation:

1. Laboratory for Translational Breast Cancer Research, Department of Oncology KU Leuven Leuven Belgium

2. Stanford University School of Medicine Palo Alto CA USA

3. University of Pittsburgh UPMC Hillman Cancer Center, and Magee Womens Research Institute Pittsburgh PA USA

4. Peter MacCallum Cancer Centre Melbourne Australia

5. Sir Peter MacCallum Department of Oncology The University of Melbourne Parkville Australia

6. Center for Precision Medicine City of Hope National Medical Center Duarte CA USA

7. University of Utah Huntsman Cancer Institute Salt Lake City UT USA

8. Memorial Sloan Kettering Cancer Center New York NY USA

9. UCL Cancer Institute University College London London UK

10. Cancer Research UK, and UCL Cancer Trials Centre University College London London UK

11. Cancer Evolution and Genome Instability Laboratory The Francis Crick Institute London UK

12. Cancer Research UK Lung Cancer Centre of Excellence UCL Cancer Institute London UK

13. Department of Medical Oncology University College London Hospitals London UK

14. Cancer Metastasis Laboratory University College London Cancer Institute London UK

15. University of Washington Seattle WA USA

16. University of Michigan Ann Arbor MI USA

17. University of North Carolina, Lineberger Comprehensive Cancer Center Chapel Hill NC USA

18. Department of Molecular and Cellular Pathology, Graduate School of Medical Sciences Kanazawa University Kanazawa Japan

19. Department of Cellular and Organ Pathology, Graduate School of Medicine Akita University Akita Japan

20. Department of Pathology, Forensic and Insurance Medicine Semmelweis University Budapest Hungary

21. National Institute of Oncology Budapest Hungary

22. Division of Oncology, Department of Internal Medicine and Oncology Semmelweis University Budapest Hungary

23. Department of Forensic Medicine University Hospitals Leuven Leuven Belgium

24. Department of Pathology University Hospitals Leuven Leuven Belgium

Abstract

AbstractWhile there is a great clinical need to understand the biology of metastatic cancer in order to treat it more effectively, research is hampered by limited sample availability. Research autopsy programmes can crucially advance the field through synchronous, extensive, and high‐volume sample collection. However, it remains an underused strategy in translational research. Via an extensive questionnaire, we collected information on the study design, enrolment strategy, study conduct, sample and data management, and challenges and opportunities of research autopsy programmes in oncology worldwide. Fourteen programmes participated in this study. Eight programmes operated 24 h/7 days, resulting in a lower median postmortem interval (time between death and start of the autopsy, 4 h) compared with those operating during working hours (9 h). Most programmes (n = 10) succeeded in collecting all samples within a median of 12 h after death. A large number of tumour sites were sampled during each autopsy (median 15.5 per patient). The median number of samples collected per patient was 58, including different processing methods for tumour samples but also non‐tumour tissues and liquid biopsies. Unique biological insights derived from these samples included metastatic progression, treatment resistance, disease heterogeneity, tumour dormancy, interactions with the tumour micro‐environment, and tumour representation in liquid biopsies. Tumour patient‐derived xenograft (PDX) or organoid (PDO) models were additionally established, allowing for drug discovery and treatment sensitivity assays. Apart from the opportunities and achievements, we also present the challenges related with postmortem sample collections and strategies to overcome them, based on the shared experience of these 14 programmes. Through this work, we hope to increase the transparency of postmortem tissue donation, to encourage and aid the creation of new programmes, and to foster collaborations on these unique sample collections. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Funder

Peter MacCallum Foundation

Susan G. Komen

Breast Cancer Research Foundation

Publisher

Wiley

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3